Truist Financial Corp Has $33.09 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Truist Financial Corp lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 59.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 168,411 shares of the medical research company’s stock after selling 242,657 shares during the quarter. Truist Financial Corp’s holdings in IQVIA were worth $33,094,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in IQV. Creative Planning increased its stake in IQVIA by 17.8% in the 3rd quarter. Creative Planning now owns 21,013 shares of the medical research company’s stock valued at $4,980,000 after buying an additional 3,176 shares during the period. Blue Trust Inc. increased its stake in IQVIA by 266.5% in the 3rd quarter. Blue Trust Inc. now owns 1,030 shares of the medical research company’s stock valued at $244,000 after buying an additional 749 shares during the period. Raleigh Capital Management Inc. increased its stake in IQVIA by 27.9% in the 3rd quarter. Raleigh Capital Management Inc. now owns 1,688 shares of the medical research company’s stock valued at $400,000 after buying an additional 368 shares during the period. Telos Capital Management Inc. increased its stake in IQVIA by 1.3% in the 3rd quarter. Telos Capital Management Inc. now owns 38,747 shares of the medical research company’s stock valued at $9,182,000 after buying an additional 514 shares during the period. Finally, Foundations Investment Advisors LLC increased its stake in IQVIA by 2.4% in the 3rd quarter. Foundations Investment Advisors LLC now owns 5,934 shares of the medical research company’s stock valued at $1,406,000 after buying an additional 141 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In related news, Director John G. Danhakl purchased 1,275 shares of IQVIA stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 1.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Leerink Partners reissued an “outperform” rating and issued a $248.00 target price (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Stifel Nicolaus decreased their target price on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They issued an “overweight” rating and a $250.00 target price for the company. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research report on Friday, November 1st. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $251.22.

IQVIA Price Performance

Shares of IQVIA stock opened at $193.27 on Wednesday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.81. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The firm has a fifty day moving average price of $200.15 and a two-hundred day moving average price of $217.43. The company has a market cap of $35.08 billion, a PE ratio of 25.77, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Analysts expect that IQVIA Holdings Inc. will post 10.81 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.